Broad-spectrum antiviral therapeutics

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Rider, Todd H ^a   Zook, Christina E ^a   Boettcher, Tara L ^a   Wick, Scott T ^a   Pancoast, Jennifer S ^a   Zusman, Benjamin D ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DOUBLE STRANDED RNA; DOUBLE STRANDED RNA ACTIVATED CASPASE OLIGOMERIZER; UNCLASSIFIED DRUG; VIRUS RNA; CASPASE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL SUSCEPTIBILITY; APOPTOSIS; ARENAVIRUS; ARTICLE; BUNYAVIRUS; CELL VIABILITY; CONTROLLED STUDY; CROSS LINKING; DENGUE VIRUS; DRUG DESIGN; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG TISSUE LEVEL; FEMALE; HUMAN; HUMAN CELL; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MOUSE; MURINE ENCEPHALOMYELITIS VIRUS; NONHUMAN; PROVOCATION TEST; RHINOVIRUS; TREATMENT DURATION; TREATMENT PLANNING; VIRUS LOAD; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CYTOLOGY; DRUG EFFECT; FIBROBLAST; INTRANASAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; VIROLOGY; VIRUS;

DENGUE VIRUS; MAMMALIA; MUS; ORTHOBUNYAVIRUS; REYNOSIA GUAMA;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIVIRAL AGENTS; APOPTOSIS; CASPASES; CELL LINE; FIBROBLASTS; HUMANS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; RNA, DOUBLE-STRANDED; VIRUSES;

EID: 79960828399     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022572     Document Type: Article

References (30)

1. Kräusslich HG, Bartenschlager R, eds. (2009) Handbook of Experimental Pharmacology 189: Antiviral Strategies Berlin Springer.
2. Demberg T, Robert-Guroff M, (2009) Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol 28: 20-48.
3. Boomker JM, de Leij LF, The TH, Harmsen MC, (2005) Viral chemokine-modulatory proteins: tools and targets. Cytokine Growth Factor Rev 16: 91-103.
4. Knipe DM, Howley PM, eds. (2006) Fields Virology, 5th ed Philadelphia Lippincott Williams & Wilkins.
5. Samuel CE, (2004) Knockdown by RNAi-proceed with caution. Nat Biotechnol 22: 280-282.
6. Sadler AJ, Williams BRG, (2008) Interferon-inducible antiviral effectors. Nat Rev Immunol 8: 559-568.
7. Yoneyama M, Fujita T, (2010) Recognition of viral nucleic acids in innate immunity. Rev Med Virol 20: 4-22.
8. Sadler AJ, Williams BR, (2007) Structure and function of the protein kinase R. Curr Top Microbiol Immunol 316: 253-292.
9. Wu S, Kaufman RJ, (1996) Double-stranded (ds) RNA binding and not dimerization correlates with the activation of the dsRNA-dependent protein kinase (PKR). J Biol Chem 271: 1756-1763.
10. Hovanessian AG, Justesen J, (2007) The human 2′-5′oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2′-5′ instead of 3′-5′ phosphodiester bond formation. Biochimie 89: 779-788.
11. Bisbal C, Silverman RH, (2007) Diverse functions of RNase L and implications in pathology. Biochimie 89: 789-798.
12. Kawai T, Akira S, (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-84.
13. Placido D, Brown BA, Lowenhaupt K, Rich A, Athanasiadis A, (2007) A left-handed RNA double helix bound by the Zα domain of the RNA-editing enzyme ADAR1. Structure 15: 395-404.
14. Pop C, Salvesen GS, (2009) Human caspases: activation, specificity, and regulation. J Biol Chem 284: 21777-21781.
15. Qin H, Srinivasula SM, Wu G, Fernandes-Alnemri T, Alnemri ES, et al. (1999) Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1. Nature 399: 549-557.
16. Bao Q, Shi Y, (2007) Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ 14: 56-65.
17. Eberstadt M, Huang B, Chen Z, Meadows RP, Ng SC, et al. (1998) NMR structure and mutagenesis of the FADD (Mort1) death-effector domain. Nature 392: 941-945.
18. Muppidi JR, Lobito AA, Ramaswamy M, Yang JK, Wang L, et al. (2006) Homotypic FADD interactions through a conserved RXDLL motif are required for death receptor-induced apoptosis. Cell Death Differ 13: 1641-50.
19. Randall RE, Goodbourn S, (2008) Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 89: 1-47.
20. Weber F, Haller O, (2007) Viral suppression of the interferon system. Biochimie 89: 836-842.
21. Langland JO, Kash JC, Carter V, Thomas MJ, Katze MG, et al. (2006) Suppression of proinflammatory signal transduction and gene expression by the dual nucleic acid binding domains of the vaccinia virus E3L proteins. J Virol 80: 10083-10095.
22. Galluzzi L, Brenner C, Morselli E, Touat Z, Kroemer G, (2008) Viral control of mitochondrial apoptosis. PLoS Pathogens 4: e1000018.
23. Postigo A, Ferrer PE, (2009) Viral inhibitors reveal overlapping themes in regulation of cell death and innate immunity. Microbes Infect 11: 1071-1078.
24. Nogal ML, González de Buitrago G, Rodríguez C, Cubelos B, Carrascosa AL, et al. (2001) African swine fever virus IAP homologue inhibits caspase activation and promotes cell survival in mammalian cells. J Virol 75: 2535-43.
25. Callus BA, Vaux DL, (2007) Caspase inhibitors: viral, cellular and chemical. Cell Death Differ 14: 73-78.
26. Rider TH, (2006) Anti-pathogen treatments. U.S. Patent 7,125,839.
27. Rider TH, (2009) Anti-pathogen treatments. U.S. Patent 7,566,694.
28. Gump JM, Dowdy SF, (2007) TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol Med 13: 443-448.
29. Ho A, Schwarze SR, Mermelstein SJ, Waksman G, Dowdy SF, (2001) Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res 61: 474-477.
30. Goun EA, Pillow TH, Jones LR, Rothbard JB, Wender PA, (2006) Molecular transporters: synthesis of oligoguanidinium transporters and their application to drug delivery and real-time imaging. ChemBioChem 7: 1497-1515.